Endometrial Cancer Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Global Endometrial Cancer Market Insights & Size and it is Segmented by Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, and Other Types of Therapies), Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, and Other Diagnosis Methods), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for the above segments.

Endometrial Cancer Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Endometrial Cancer Industry Overview

The endometrial cancer market is moderately competitive and consists of several major players. Due to the rising prevalence of cancer, there are several products under trial; henceforth, it is expected that a few other smaller players may enter the market. Some of the major players in the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Siemens Healthineers (Varian Medical Systems, Inc.), among others.

Endometrial Cancer Market Leaders

  1. Elekta AB

  2. Karyopharm Therapeutics

  3. Eisai Co., Ltd.

  4. GSK plc

  5. Siemens Healthineers (Varian Medical Systems, Inc.)

  6. *Disclaimer: Major Players sorted in no particular order
endocan.png